Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07431177 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Study acronym: VITESS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 76 → 83 locations
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 6 of 6 entries
  2. Trial sites expanded: 72 → 76 locationsv17
  3. Trial sites expanded: 52 → 72 locationsv16
  4. Trial sites expanded: 33 → 52 locationsv15
  5. Trial sites expanded: 28 → 33 locationsv14
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 26 to 28v13
  2. Study sites: 24 to 26v12
  3. Study sites: 22 to 24
    • Primary completion date: Jun 23, 2028 to Jun 6, 2028
    • Study completion date: Feb 14, 2030 to Jan 28, 2030
    v11
  4. Study sites: 20 to 22v10
  5. Study sites: 18 to 20v9
  1. Trial sites expanded: 15 → 18 locationsv8
  2. Study sites: 13 to 15v7
  3. Trial sites expanded: 10 → 13 locationsv6
  4. Study sites: 8 to 10v5
  5. Study sites: 6 to 8v4
  6. Study sites: 3 to 6
    • Primary completion date: Jul 15, 2028 to Jun 23, 2028
    • Study completion date: Mar 8, 2030 to Feb 14, 2030
    v3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Apr 1, 2026 to Mar 9, 2026
    v2
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Trial Details
NCT Number NCT07431177
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Non-segmental Vitiligo
Related terms Vitiligo
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov